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Introduction 1 
The diagnosis of tuberculosis (TB) disease in resource-poor settings remains challenging. 2 
Several independent studies have reported on the limitations of current techniques in 3 
diagnosing TB.1-4 There is a lack of simple field-friendly diagnostic tools and markers of 4 
immune activation and modulation of cytokine networks during intracellular infections might 5 
provide opportunities to develop appropriate tools.5-11 6 
The Interferon gamma (IFN-γ) release assays (IGRAs) with high specificity and accuracy in 7 
the diagnosis of Mycobacterium tuberculosis (Mtb) infection have been widely employed in 8 
the immune-based diagnosis of Mtb infection and have some advantages over the tuberculin 9 
skin test.12 However, IGRAs are mainly useful in low incidence settings and for research 10 
advances in high burden areas as their major disadvantage is the inability to differentiate 11 
between active and latent TB.12,13 The discovery of secreted biomarkers similar to the gene 12 
expression signatures that were recently identified and that differentiate between these two 13 
infection states and which can be further developed into a rapid point of care test would be a 14 
major boost in TB diagnosis.14 15 
Recently, there has been an upsurge in the alternative use of novel Mtb antigens and host 16 
markers besides IFN-γ in Mtb-specific antigen stimulated whole blood culture assay for 17 
exploring the diagnosis of TB.15 We have previously measured many of these host markers 18 
including tumour necrosis factor (TNF-α), interferon-inducible protein (IP-10), epidermal 19 
growth factor (EGF), macrophage inflammatory protein (MIP)-1β, vascular endothelial 20 
growth factor (VEGF) and soluble CD40 ligand (sCD40L) after stimulation with novel Mtb 21 
infection phase-dependent antigens (including TB vaccine candidate antigens, dormancy 22 
(DosR) regulon encoded antigens, TB reactivation antigens, TB resuscitation promoting 23 
factors (rpfs) and other stress response-associated antigens) in whole blood culture 24 
supernatants and some of these antigens look promising in TB disease diagnosis.16,17 25 
However, in these studies, long term (7 day) whole blood assays were employed, which is 26 
not ideal for diagnostic purposes. In a follow up to these studies, we evaluated the potential 27 
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of some of these promising antigens to elicit a host response in a short term (overnight) 28 
whole blood assay compared to the long term (7 day) whole blood assay.18 This study also 29 
evaluated the accuracy of some of these previously reported novel candidate antigens but in 30 
a larger study employing a short term (overnight), more field-friendly whole blood assay.   31 
Materials and methods 32 
Study participants 33 
All the participants presumed of having pulmonary TB who participated in this study were 34 
recruited as part of the EDCTP funded African European Tuberculosis Consortium (AE-TBC) 35 
study that was conducted across six different African countries (www.ae-tbc.eu). Participants 36 
included in the present study were recruited from field sites serving Stellenbosch University, 37 
South Africa; Makerere University, Uganda; Medical Research Council Unit, The Gambia; 38 
and Karonga Prevention Study, Malawi. Participants presented with symptoms suggestive of 39 
pulmonary TB disease such as persistent cough for more than 2 weeks and one of the 40 
following: fever, recent loss of weight, night sweats, haemolysis, chest pain or loss of 41 
appetite. Participants were eligible for the study if they were 18 years or older, willing to give 42 
written informed consent, including for HIV testing using a rapid test (Abott, Germany) and 43 
sample storage. The exclusion criteria included severe anaemia (HB<10g/l), pregnancy, 44 
other known diseases such as diabetes mellitus, current anti-TB treatment, anti-TB 45 
treatment in the last 90 days, use of quinolone or aminoglycoside antibiotics in the past 60 46 
days, and not been resident in the study area for more than 3 months. A case report form 47 
was completed for each participant before the collection of blood, saliva and other intended 48 
samples including urine and sputum as required for the main study. Culture of sputum 49 
samples was done using the MGIT method (BD Biosciences) and confirmation of isolated 50 
Mtb complex in all positive cultures was carried out by an Mtb complex specific PCR or 51 
standard biochemical methods, dependent on the facilities available at the study site.4 52 
Additionally, 3 ml of blood was collected from the participants for the performance of QFT-IT 53 
assay, which was carried out according to the manufacturer’s instruction as previously 54 
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described.19 The Human Ethics Research Committee of the University of Stellenbosch gave 55 
approval for the study (N10/08/274). 56 
Reference standard for classification of study participants 57 
Prior to the commencement of recruitment of study participants, harmonized case definitions 58 
were established and used for the classification of study participants (presumed TB cases) 59 
at all study sites. Participants were classified as having definite TB, probable TB, 60 
questionable TB disease status or non TB, using a combination of clinical, radiological, and 61 
laboratory findings.45 The non TB cases were cases had a range of other diagnoses, 62 
including upper and lower respiratory tract infections (viral and bacterial infections, although 63 
attempts to identify organisms by bacterial or viral cultures were not made), and acute 64 
exacerbations of chronic obstructive pulmonary disease or asthma. No participant in the non 65 
TB group underwent TB treatment during the 6 month follow up of the study. In assessing 66 
the diagnostic accuracy of the markers investigated in the present study, all the definite and 67 
probable TB cases were classified as “TB”, and then compared to the non TB cases, 68 
whereas questionables were excluded (Figure 1).   69 
 70 
Whole blood culture assay (WBA) 71 
At enrolment, 10ml of heparinised blood was collected from all participants and transported 72 
at ambient conditions within two hours of collection to the laboratory where the WBA was 73 
performed. The antigens that were used came from two sources namely: Leiden University 74 
Medical Center (LUMC), The Netherlands, and the Statens Serum Institut (SSI), Denmark. 75 
ESAT-6 and CFP-10 are two separate antigens, but were measured together as a fusion 76 
protein (ESAT-6/CFP-10) in this study. ESAT-6/CFP-10 and RV0081 were selected for the 77 
current study because of the promising accuracy shown by host markers elicited by these 78 
antigens in our previous studies16-18 whereas Rv1284 and Rv2034 were selected because of 79 
the promise already shown by the antigens as TB diagnostic and vaccine candidates in 80 
previous studies.20,21 Prior to their usage the four lyophilised antigens were reconstituted in 81 
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sterile 1X PBS. The reconstituted antigens were then diluted in sterile 1x PBS, mixed with 82 
undiluted whole blood from each study participant at a final concentration of 10µg/ml, and 83 
incubated overnight (20-24hours) in 24-well tissue culture plates (Corning Corstar, Sigma) 84 
as previously described.18 Sterile 1x PBS (Lonza, Cat #: 17-517Q) was used as the negative 85 
control.  86 
Luminex multiplex immunoassay 87 
This prospective study included 322 TB and non TB cases and was evaluated using a 88 
Luminex multiplex cytokine platform which is based on simultaneous detection and 89 
cytometric quantification of different cytokines in a sample. The concentrations of 42 host 90 
markers including interleukin (IL)-1β, IL-1Rα, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-91 
12, IL-13, IL-15, IL-17, eotaxin, fibroblast growth factor (FGF) basic, granulocyte colony 92 
stimulating factor (G-CSF), granulocyte monocyte colony stimulating factor (GM-CSF), IFN-93 
γ, interferon inducible protein (IP)-10, monocyte chemotactic protein (MCP)-1, macrophage 94 
inflammatory protein (MIP)-1α, platelet derived growth factor BB (PDGF-BB), MIP-1β, 95 
RANTES, TNF-α, vascular endothelial growth factor (VEGF), eotaxin-2, BCA-1, 6Ckine, 96 
SCF, TRAIL, ENA, ferritin, fibrinogen, procalcitonin, serum amyloid protein A (SAA), tissue 97 
plasminogen activator, serum amyloid protein P (SAP), CRP, haptoglobin and α-2 98 
macroglobulin, were evaluated in WBA supernatants of all the study participants. This was 99 
done using Milliplex kits (Merck Millipore, St. Charles, Missouri, USA) and Bio-Plex kits (Bio 100 
Rad Laboratories, Hercules, CA, USA) on the Bio-Plex™ platform according to the 101 
manufacturer’s instructions. Standard curves were generated from the serial dilutions that 102 
were made from the assay controls supplied and matched against the cytokine concentration 103 
for quantification. The concentrations of all the analytes in the quality control reagents were 104 
found to be within the ranges as expected. The Bio-Plex manager version 6.1 was used for 105 
bead acquisition and analysis of median fluorescence intensity. 106 
 107 
 108 
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Statistical analysis 109 
Statistical differences in analyte levels were evaluated by the Mann Whitney U test for non-110 
parametric data analysis. The diagnostic accuracies of individual antigen-specific or 111 
ustimulated responses for TB disease were ascertained by receiver operator characteristics 112 
(ROC) curve analysis. Cut-off levels for estimation of sensitivity and specificity were selected 113 
based on the Youden’s Index. The predictive abilities of combinations of unstimulated and 114 
antigen-specific host markers for TB disease and non TB were investigated by performing 115 
best subsets general discriminant analysis (GDA). Data were randomly partitioned into a 116 
70% training data set, which was used for model building and 30% test set, which was used 117 
to verify the accuracy of the different models. The leave-one-out cross validation approach 118 
was used to test the prediction accuracy of biosignatures after data was stratified according 119 
to HIV status, due to the relatively limited number of HIV infected individuals. Data were 120 
analyzed using GraphPad prism, version 5.00 for Windows (Graphpad Software, San Diego 121 
California, USA) and Statistica (Statsoft, Ohio, USA). 122 
Results 123 
Study participants 124 
 125 
A total of 322 participants were enrolled into this study, 106 (33%) of who were cultures 126 
positive TB cases (Figure 1). Of the 322 study participants, 168 (52%) were males and 24 127 
(23%) of the 106 TB cases were HIV co-infected. The demographic and clinical information 128 
of the participants are shown in table 1. 129 
Potential of host markers produced by unstimulated supernatants in 130 
discriminating between individuals with TB and non TB disease  131 
When the analyte levels detected in the unstimulated control supernatants in TB patients 132 
were compared to the levels obtained in the non TB group (50% of this group were QFT-IT 133 
positive), the unstimulated levels of 14 out of the 42 host markers evaluated showed 134 
significant differences. The concentrations of these markers including CRP, Ferritin, IP-10, 135 
IL-6, IL-7, IL-9, IL-13, IFN-γ, VEGF, Haptoglobin, SAP, PCT and SAA were significantly 136 
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higher in the TB group (Table 2).  When the diagnostic potentials of these unstimulated host 137 
markers were evaluated by ROC curve analysis, four analytes including CRP, IP-10, Ferritin 138 
and SAA had an area under the ROC curve (AUC) of ≥ 0.85, ≥ 0.74, ≥ 0.79 and ≥ 0.77 139 
respectively, in unstimulated samples. At their optimal unstimulated cut-off values, SAA had 140 
a sensitivity and specificity of 81% and 72%, ferritin 70% for both sensitivity and specificity, 141 
IP-10 had 77% sensitivity and 71% specificity for ascertaining TB disease. The best 142 
performance characteristic was with unstimulated CRP with a sensitivity and specificity of 143 
80% (Table 2, Figure 3). The high AUC recorded for some of these markers support their 144 
diagnostic potential.  145 
Utility of host markers detected in overnight antigen-stimulated culture 146 
supernatants in the diagnosis of TB disease 147 
The unstimulated control levels for the different host markers were subtracted from the 148 
antigen-stimulated responses for each study participant before the analysis of the data. In 149 
response to Mtb-specific antigenic stimulation by ESAT-6/CFP-10, median concentrations of 150 
IP-10, IFN-γ, IL-1Rα, tPA and TRAIL were significantly higher in the TB group (p<0.05) 151 
(Table 2, Figure 2). Following stimulation with Rv2034, IL-2, IL-17 and FGF basic levels 152 
were significantly higher in TB cases whereas ferritin was higher in non TB. Rv1284 elicited 153 
the production of significantly high levels of IL-2 in the non TB cases, whereas only tPA 154 
responses were significantly different between the TB and non TB cases after stimulation 155 
with Rv0081 (Table 2). When the diagnostic accuracy of individual antigen-specific host 156 
markers were investigated by ROC curve analysis, the AUCs for ESAT-6/CFP-10 stimulated 157 
IP-10 and IFN-γ were ≥ 0.64 respectively. Antigen-specific level of IP-10 had the best 158 
sensitivity of 60% and specificity of 65%. The AUC’s of Rv1284-specific and Rv2034-specific 159 
markers performed poorly in general. Only Rv2034-specific level of IL-2 attained 0.60 (Table 160 
2, Figure 3). 161 
 162 
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Ability of cytokine responses to discriminate between LTBI and uninfected 163 
controls 164 
When the concentration of host markers detected in QFT-IT positive non TB cases (LTBI) 165 
were compared to the levels obtained in the QFT-IT negative non TB cases (uninfected 166 
controls), the unstimulated levels of IL-1β, IL-1Rα, IL-6, IL-10, IL-12, MIP-1α, TNF-α and 167 
were significantly higher in the uninfected controls. Only unstimulated levels of eotaxin were 168 
significantly higher in LTBI subjects. When the host markers elicited after stimulation with the 169 
different antigens were compared between the two groups, most of the discriminatory 170 
markers were found in ESAT-6/CFP-10 stimulated supernatants. ESAT-6/CFP-10 -specific 171 
levels of IL-1Rα, IL-2, IL-4, IL-5, IL-13, IL-15, FGF basic, GM-CSF, IFN-γ, IP-10, MCP-1, 172 
MIP-1α and Eotaxin-2 were significantly higher in the LTBI group. Similarly, Rv2034-specific 173 
levels of IL-8, IL-15, MCP-1 and MIP-1α, and Rv1284-specific levels of G-CSF, MCP-1 and 174 
PDGF-BB were significantly higher in the LTBI. Stimulation with Rv0081 failed to elicit any 175 
response. When the diagnostic accuracies of the markers detected in the culture 176 
supernatants were evaluated by ROC curve analysis, only ESAT-6/CFP-10-specific levels of 177 
IP-10, IFN-γ, GM-CSF, IL-2 and IL-13 discriminated between the two groups with AUC ≥ 178 
0.70.  Out of these five markers, ESAT-6/CFP-10-specific level of IP-10 had the best 179 
sensitivity and specificity of 75% and 72% respectively. Although ESAT-6/CFP-10-specific 180 
IL-5 and eotaxin-2, Rv2034-specific MCP-1, and Rv1284-specific PDGF-BB all discriminated 181 
between the two groups with sensitivities >80%, the specificities of all these markers were 182 
poor, ranging between 38-50% (Table 3). 183 
Abilities of combinations of analytes in the general discriminant analysis 184 
models in discriminating between TB and non TB. 185 
To evaluate the predictive abilities of combinations of analytes for TB and no TB disease 186 
data obtained from all study participants were analysed by general discriminant analysis 187 
(GDA), regardless of the HIV infection status of the study participants.  The unstimulated and 188 
antigen-specific responses of each host marker were treated as separate variables, in order 189 
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to evaluate the contribution of both classes of markers in predictive models. We randomly 190 
partitioned all the data from the measurement of the different markers into a 70% training 191 
data set for model building, and 30% for a test set for the verification of the models. A 192 
combination of six markers IP-10 Ag-Nil, IFN-γ Ag-Nil, IP-10Nil, Ferritin Nil, SAA Nil, and CRP Nil 193 
accurately predicted 77% TB cases and 84% of the non TB cases in the training set, 194 
regardless of HIV infection status. In the test set, the six-marker biosignature accurately 195 
predicted 83% of the TB cases and 78% of the non TB cases (Table 4). 196 
To investigate the influence of HIV infection on the accuracy of the biosignatures, data was 197 
stratified according to HIV status, and the GDA procedure repeated. In the HIV uninfected 198 
group the six-marker biosignature (IP-10 Ag-Nil, IFN-γ Ag-Nil, IP-10Nil, Ferritin Nil, SAA Nil, and CRP 199 
Nil) diagnosed TB disease with a sensitivity of 83% and specificity of 90% in the training data 200 
set, and a sensitivity of 88% and specificity of 82% in the test dataset. However, the 201 
combination of these analytes performed less well in the HIV infected patients as only 64% 202 
of the TB cases and 80% of the non TB cases were correctly classified in the resubstitution 203 
classification matrix. After leave-one-out cross validation, the biomarker combination only 204 
resulted in the correct prediction of 52% of the TB cases and 76% non TB (Table 4). The 205 
frequency of the different analytes in the top 20 models for discriminating between TB 206 
disease and non TB in all study participants is shown in figure 4. 207 
Discussion 208 
The development of a new, relatively rapid, and accurate test, that does not rely on sputum, 209 
which can be difficult to obtain in some patient groups, and which does not reflect the site of 210 
infection in extrapulmonary TB, would be a major advance in the TB diagnostic field. The 211 
measurement of a small number of analytes that differentiates active TB from LTBI in the 212 
blood in a short-term overnight assay, might fulfil this need.19 Test results would be available 213 
within 48 hours, rather than after several weeks as is the case with sputum culture. In this 214 
study we investigated the potential accuracy of host markers detected in supernatants, after 215 
stimulation of whole blood with Mtb infection phase-dependent antigens, in an overnight 216 
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culture assay. We have shown that multiple biomarkers detected in the antigen-stimulated 217 
and unstimulated supernatants can contribute to a diagnostic signature with the ability to 218 
discriminate between active TB and non TB. A biosignature of six analytes showed 219 
promising results especially in HIV uninfected individuals. We previously reported on the 220 
potential of host markers produced after stimulation of blood cells with novel Mtb infection 221 
phase-dependent antigens, including Rv0081, Rv0867c, Rv2389c, Rv1009 and Rv2032 in 222 
the diagnosis of TB disease.16,17 However, the 7-day WBA used in that work would not be 223 
optimal and useful as a TB diagnostic tool, especially in resource limited settings. Follow-up 224 
work evaluated a down selected number of these antigens in the 7-day and overnight 225 
cultured assays18 and the present study is a validation of that pilot data.  226 
We enrolled 322 participants with presumed TB and confirmed active disease in 106, 227 
whereas active TB was excluded in 216.  Comparison of the levels of markers in these two 228 
groups, irrespective of their HIV status, and QFT-IT results was performed. Although a sub-229 
group comparison of these markers in the different Mtb infection groups was not our primary 230 
objective as we were looking for diagnostic tests suitable for the accurate diagnosis of active 231 
TB in high endemic settings, with a high prevalence of LTBI, we evaluated the utility of 232 
multiple analyte signatures in the diagnosis of TB disease in different HIV and QFT-IT sub 233 
groups. We identified several markers that discriminated between latently infected 234 
individuals and uninfected groups.  235 
Antigen-specific host markers measured in the overnight WBA in this study did not show 236 
much diagnostic potential as the top single markers observed; IFN-γ and IP-10, only 237 
achieved an AUC of 64% in discriminating between TB disease and non TB. However, 238 
unstimulated levels of SAA, ferritin, CRP and IP-10 were the most promising single markers 239 
obtained, reaching AUC ≥70%. As observed in our previous studies16,17 the predictive 240 
abilities of these markers improved when they were used in combinations. Indeed, in this 241 
study, a six analyte-model showed an improved diagnostic potential. The results of the acute 242 
phase proteins: CRP and SAA, are consistent with the results from the pilot study where 243 
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these markers also featured strongly and were included in the top four-analyte multi marker 244 
models.18 In contrast to our previous observations none of VEGF, TGF-α or EGF, which was 245 
prominent in the best discriminatory marker model in the 7-day assay, was included into the 246 
present models. The larger sample size in the present study and the use of the short term 247 
assay are probably responsible for the discrepancy.  248 
Rv0081 is a DosR regulon encoded antigen and several studies have shown that the DosR 249 
regulon of Mtb is associated with latency, nutrient starvation, hypoxia and low nitric oxide or 250 
pH.22-27 Despite the diagnostic potential of this antigen, it did not discriminate between TB 251 
and non TB with high sensitivity and specificity and failed to differentiate LTBI from 252 
uninfected controls. The evaluation of this antigen in combination with other antigens in 253 
previous study did not improve its accuracy.16 Rv0081 elicited tPA responses that were 254 
significantly higher in TB cases, in comparison to the non TB group. In contrast to our 255 
previous studies, which were conducted in household contacts (HHC) of TB cases, the 256 
present study did not recruit contacts as the control group. DosR regulon antigens might be 257 
recognised more frequently by people with recent exposure and infection.23, 28-30 IFN-γ 258 
elicited by ESAT-6/CFP-10 is a commonly used marker for TB infection and although it does 259 
not discriminate between active TB and LTBI on its own, it was included most frequently in 260 
the GDA models. This classical antigen also elicited SAA, CRP and ferritin responses. 261 
These acute phase proteins are mainly produced in the liver as a result of inflammation and 262 
it is not a surprise that these markers, particularly the unstimulated levels, were included in 263 
the top analyte models. SAA and CRP are also produced by macrophages and peripheral 264 
blood mononuclear cells (PBMCs), respectively,31,32 are being extensively employed as 265 
biomarkers in many disease conditions including pulmonary infections.33,34 The potential 266 
usefulness of SAA and CRP in serum in the diagnosis of TB has been shown in previous 267 
studies46 although no current TB diagnostic tests use these markers.35,36 IP-10 is a 268 
chemokine secreted by monocytes with direct interaction with antigen specific T-cells and 269 
has been widely researched as an alternative TB immunodiagnostic biomarker.37,38 The 270 
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levels of stimulated IP-10 was higher in TB disease in our study compared to non TB and 271 
this is in agreement with other studies where IP-10 differentiated better between active TB 272 
cases and unexposed individuals than IFN-γ release assays (IGRA).39,40 Several studies 273 
have shown that the combination of both IFN-γ and IP-10 could significantly enhance 274 
diagnostic performance.41-44 275 
The main limitation of our study was the evaluation of fewer antigens than in our previous 276 
studies as the down selection of the number of antigens from our pilot work demonstrates 277 
the risk for false discovery when a large number of antigens are evaluated in a relatively 278 
small number of samples. Antigens can be falsely included or excluded due to insufficient 279 
power of the pilot studies. Alternatively, however, the use of shorter term assay here as 280 
opposed to the use of long term assays in our previous study might have biased towards 281 
responses to a subset of the originally identified antigens only, possibly due to differences in 282 
response kinetics. Our results furthermore highlight the fact that multi-marker biosignatures 283 
hold promise above the use of single markers. Finally, the results suggest that ex vivo 284 
samples like plasma and serum may hold promise for the discovery of such biosignatures, 285 
as no added accuracy was obtained through stimulation with Mtb antigens. We conclude that 286 
large future studies should focus on ex vivo markers.   287 
Conclusion 288 
We identified a biosignature of six unstimulated and mycobacteria-specific host markers in 289 
antigen-stimulated overnight WBAs that showed potential in the diagnosis of TB disease with 290 
an accurate prediction of 77% TB cases and 84% non TB cases. The sensitivity and 291 
specificity of this 6-analyte model was better in HIV uninfected patients but as a large 292 
percentage of African TB patients have HIV co-infection, this approach has limited future 293 
potential. These markers could, however, be adjunctive markers in the diagnosis of TB 294 
disease where sputum is difficult to obtain or where extrapulmonary TB is presumed. Future 295 
studies in children and extrapulmonary TB patients should evaluate additional novel Mtb 296 
antigens, ex-vivo unstimulated markers such as in serum and plasma, and host markers 297 
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possibly using non-biased approaches such as proteomics to improve sensitivity before field-298 
friendly versions of the stimulation assays are developed. 299 
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